Enanta Pharmaceuticals | ENTA - Assets


Enanta Pharmaceuticals reported $329.5M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Anika Therapeutics USD 190.27M 833K Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novavax USD 1.18B 3.38M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025